Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBP-1118
- Development stage
- Preclinical
- Lead developer
- Infant Bacterial Therapeutics
- Modality
- Peptides, Small Molecules
- Administration
- Enteral
01
Overview
IBP-1118 is a small molecule dipeptide consisting of arginine and glutamine (Arg-Gln) being developed by Infant Bacterial Therapeutics (IBT) for the prevention of retinopathy of prematurity (ROP). ROP is a leading cause of blindness in premature infants, characterized by abnormal retinal vascularization. Developed in collaboration with researchers from the University of Florida, IBP-1118 aims to promote healthy retinal development and prevent pathological neovascularization. The drug candidate is intended for enteral administration and has been granted Orphan Drug Designation by the FDA for this indication.
- Other names
- arginine-glutamineArg-Gln
Beyond the preview
Go deeper on IBP-1118.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBP-1118.